CLINICAL TRIALS PROFILE FOR ARICEPT
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Aricept
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000173 ↗ | Memory Impairment Study (Mild Cognitive Impairment Study) | Completed | Alzheimer's Disease Cooperative Study (ADCS) | Phase 3 | 1999-03-01 | The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months. |
| NCT00000173 ↗ | Memory Impairment Study (Mild Cognitive Impairment Study) | Completed | National Institute on Aging (NIA) | Phase 3 | 1999-03-01 | The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months. |
| NCT00004807 ↗ | Study of the Pathogenesis of Rett Syndrome | Completed | Johns Hopkins University | N/A | 1995-01-01 | OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery. |
| NCT00004807 ↗ | Study of the Pathogenesis of Rett Syndrome | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | N/A | 1995-01-01 | OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery. |
| NCT00018278 ↗ | Electrophysiologic Measures of Treatment Response in Alzheimer Disease | Completed | US Department of Veterans Affairs | Phase 4 | 1998-10-01 | The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response. |
| NCT00018278 ↗ | Electrophysiologic Measures of Treatment Response in Alzheimer Disease | Completed | VA Office of Research and Development | Phase 4 | 1998-10-01 | The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response. |
| NCT00024531 ↗ | Lipitor as a Treatment for Alzheimer's Disease | Completed | Pfizer | Phase 2 | 2000-10-01 | The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Aricept
Condition Name
Clinical Trial Locations for Aricept
Trials by Country
Clinical Trial Progress for Aricept
Clinical Trial Phase
Clinical Trial Sponsors for Aricept
Sponsor Name
